专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011150226A1 METHOD FOR DETECTING NUCLEIC ACIDS BASED ON AGGREGATE FORMATION 审中-公开
标题翻译：基于聚集形成检测核酸的方法
公开(公告)号：WO2011150226A1
公开(公告)日：2011-12-01
申请号：PCT/US2011/038166
申请日：2011-05-26
申请人： LANDERS, James, P. , KELLY, Kimberly, A. , LI, Jingyi , LESLIE, Daniel, C.
发明人： LANDERS, James, P. , KELLY, Kimberly, A. , LI, Jingyi , LESLIE, Daniel, C.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6888 , C12Q1/6816 , C12Q1/689 , C12Q1/70 , C12Q2565/113 , C12Q2563/143 , C12Q2537/125 , C12Q2563/149
摘要： The invention provides methods to detect or determine the presence or amount of a pathogen, such as a virus or bacterium, in a sample or the amount of cells based on the detection of their genomic DNA. The method employs magnetic substrates and subjects the sample and the magnetic substrate to forms of energy so as to induce aggregate formation and detects the aggregates.
摘要翻译：本发明提供了检测或确定样品中病原体如病毒或细菌的存在或数量或基于其基因组DNA检测的细胞数量的方法。该方法采用磁性底物，并使样品和磁性底物形成能量，以便诱导聚集体形成并检测聚集体。

2. 发明申请

WO2011057078A3 COMPOSITIONS AND METHODS FOR DETECTING PLECTIN-1 AS A BIOMARKER FOR CANCER 审中-公开
标题翻译：检测PLECTIN-1作为癌症生物标志物的组合物和方法
公开(公告)号：WO2011057078A3
公开(公告)日：2011-09-22
申请号：PCT/US2010055632
申请日：2010-11-05
申请人： UNIV VIRGINIA PATENT FOUND , KELLY KIMBERLY A
发明人： KELLY KIMBERLY A
IPC分类号： G01N33/68 , G01N33/574 , G01N33/58
CPC分类号： A61K51/088 , A61K47/64 , A61K49/0002 , A61K51/0482 , A61K51/065 , C07K7/06 , C07K14/00 , G01N33/531 , G01N33/574 , G01N2333/4724
摘要： The present invention provides compositions and methods useful for diagnostic and imaging techniques for detecting and localizing the biomarker Plectin-1. The present invention provides multimeric peptide ligand complexes for targeting Plectin-1, such as the multimeric peptide ligand complex having the formula (ßAKTLLPTPGGS(PEG5000))4 KKKKDOTAßA-NH2, to which imaging agents and/or therapeutic agents can be conjugated.
摘要翻译：本发明提供了用于检测和定位生物标志物网蛋白-1的诊断和成像技术的组合物和方法。本发明提供了用于靶向网蛋白-1的多聚体肽配体复合物，例如具有式（βAKTLLPTPGGS（PEG5000））4KKKKDOTAASA-NH 2的多聚体肽配体复合物，可以与成像剂和/或治疗剂缀合。

3. 发明申请

WO2009005579A1 HIGH AFFINITY FLUOROCHROME BINDING PEPTIDES 审中-公开
标题翻译：高亲和力荧光素结合肽
公开(公告)号：WO2009005579A1
公开(公告)日：2009-01-08
申请号：PCT/US2008007329
申请日：2008-06-12
申请人： GEN HOSPITAL CORP , KELLY KIMBERLY , WEISSLEDER RALPH
发明人： KELLY KIMBERLY , WEISSLEDER RALPH
IPC分类号： G01N21/76
CPC分类号： C07K7/06 , C07K2319/33 , C07K2319/60
摘要： The present invention contemplates strategies comprising small molecule, cell permeable probes that allow site-specific protein labeling for visualizing biological processes. In one embodiment, the present invention contemplates a series of short peptide sequences comprising high affinity binding (i.e., for example, subnanomolar affinity (0.53 nM) for indocyanine fluorochromes. In one embodiment, the peptide sequences comprise a 5 pmol detection limit for indocyanine fluorochromes. In one embodiment, the present invention contemplates methods comprising high affinity peptide-fluorochrome binding pairs in biological applications including, but not limited to, enzyme linked immunoabsorbent assay (ELISA), fluorescence activated cell sorting (FACS), microscopy (i.e., for example scanning electromicroscopy), Western Blots, histochemistry, protein and cell based tracking both in vitro and in vivo.
摘要翻译：本发明考虑包含允许位点特异性蛋白质标记以使生物学过程可视化的小分子细胞渗透性探针的策略。在一个实施方案中，本发明设想了一系列包含高亲和力结合（即例如对于吲哚菁荧光染料的亚纳摩尔亲和力（0.53nM））的短肽序列。在一个实施方案中，肽序列包含对吲哚菁荧光染料的5pmol检测限（ELISA），荧光激活细胞分选（FACS），显微术（即，例如，但不限于，生物学应用，包括但不限于高亲和力肽 - 荧光染料结合对的方法）扫描电子显微镜），蛋白质印迹，组织化学，蛋白质和基于细胞的体外和体内跟踪。

4. 发明申请

WO2003086284A3 COLON TUMOR SPECIFIC BINDING PEPTIDES 审中-公开
公开(公告)号：WO2003086284A3
公开(公告)日：2003-10-23
申请号：PCT/US2003/010630
申请日：2003-04-07
申请人： UNIVERSITY OF UTAH RESEARCH FOUNDATION , KELLY, Kimberly, A. , JONES, David, A.
发明人： KELLY, Kimberly, A. , JONES, David, A.
IPC分类号： A61K38/00
摘要： Phage display was used to screen peptide libraries that distinguish between well-differentiated (HCT116) and poorly-differentiated colon carcinoma cells (HT29). The screening protocol used selection and subtraction on intact, viable cells, resulting in phage libraries exhibiting high binding selectivity for the poorly-differentiated HT29 cells. A nine amino acid, disulfide-constrained peptide (RPM) was identified that selectively bound and was internalized into colon cancer cells. The peptide may be used to detect colon cancer cells and also may be used to selectively deliver therapeutic agents to the cells.

5. 发明申请

WO2019168921A1 PLECTIN-TARGETED LIPOSOMES/PARP INHIBITOR IN THE TREATMENT OF CANCER 审中-公开
公开(公告)号：WO2019168921A1
公开(公告)日：2019-09-06
申请号：PCT/US2019/019752
申请日：2019-02-27
申请人： UNIVERSITY OF VIRGINIA PATENT FOUNDATION , KELLY, Kimberly, A. , DASA, Siva, Sai, Krishna
发明人： KELLY, Kimberly, A. , DASA, Siva, Sai, Krishna
IPC分类号： A61K47/69
摘要： The present invention provides compositions and methods to treat cancer.

6. 发明申请

WO2019075216A1 PLECTIN-1 BINDING ANTIBODIES AND USES THEREOF 审中-公开
公开(公告)号：WO2019075216A1
公开(公告)日：2019-04-18
申请号：PCT/US2018/055438
申请日：2018-10-11
申请人： ITI HEALTH, INC. D/B/A ZIELBIO , KELLY, Kimberly, A.
发明人： KELLY, Kimberly, A.
IPC分类号： A61K39/00 , A61K39/395 , A61K38/00 , A61K9/14 , C12P21/08 , C07K16/00
摘要： Aspects of the disclosure provide compositions and methods for treating cancer characterized by surface expression of plectin-1. The disclosure relates, in part, to combinations of therapeutic agents (e.g., anti-plectin-1 antibodies and certain small molecules) that function together (e.g., synergistically) to inhibit cancer cell growth. In some embodiments, the disclosure relates to anti-plectin-1 antibody-drug-conjugates (ADCs).

7. 发明申请

WO2016205397A2 TARGET-SPECIFIC DELIVERY OF THERAPEUTIC AGENTS 审中-公开
标题翻译：治疗药物的目标特异性递送
公开(公告)号：WO2016205397A2
公开(公告)日：2016-12-22
申请号：PCT/US2016/037668
申请日：2016-06-15
申请人： KLIBANOV, Alexander L. , FRENCH, Brent A. , KELLY, Kimberly A. , DASA, Krishna Siva Sai
发明人： KLIBANOV, Alexander L. , FRENCH, Brent A. , KELLY, Kimberly A. , DASA, Krishna Siva Sai
CPC分类号： C07K7/06 , A61K9/0019 , A61K47/62 , A61K47/6913
摘要： Isolated peptides targeting cardiovascular disease are described herein or one or more conservative amino acid substitutions, deletions or additions of such peptides and methods of use thereof for delivering payloads to specific cell types or tissues.
摘要翻译：本文描述了针对心血管疾病的分离的肽或这种肽的一种或多种保守氨基酸取代，缺失或添加及其用于将有效载体递送到特定细胞类型或组织的方法。

8. 发明申请

WO2012158502A3 COMPOSITIONS AND METHODS FOR A MYCOBACTERIUM TUBERCULOSIS DRUG SUSCEPTIBILITY TEST 审中-公开
公开(公告)号：WO2012158502A3
公开(公告)日：2012-11-22
申请号：PCT/US2012/037472
申请日：2012-05-11
申请人： UNIVERSITY OF VIRGINIA PATENT FOUNDATION , HOUPT, Eric R. , KELLY, Kimberly A. , PHOLWAT, Suporn
发明人： HOUPT, Eric R. , KELLY, Kimberly A. , PHOLWAT, Suporn
IPC分类号： C12Q1/02 , C12Q1/70
摘要： The present application discloses rapid Mycobacterium tuberculosis drug susceptibility utilizing real-time PCR of mycobacteriophage D29 DNA. One protocol involves culturing Tb isolates for 48 hours with and without drugs at critical concentrations, followed by incubation with 103 pfu/ml of D29 mycobacteriophage for 24 hours and then real-time PCR. Many drugs can be incubated instantly with Tb and phage. The change in phage DNA real-time PCR cycle threshold (Ct) between control Tb and Tb treated with drugs was calculated and correlated with conventional agar proportion drug susceptibility results. Specifically, 9 susceptible clinical isolates, 22 MDR, and 1 XDR Tb strains were used and Ct control - Ct drug cutoffs of between +0.3 and -6.0 yielded 422/429 (98%) accurate results for the drugs tested. The Ct values correlated with isolate minimal inhibitory concentration (MIC) for most agents. This D29 qPCR assay offers a rapid, accurate, 1-3 day phenotypic drug susceptibility test.

9. 发明申请

WO2011057078A2 COMPOSITIONS AND METHODS FOR DETECTING PLECTIN-1 AS A BIOMARKER FOR CANCER 审中-公开
标题翻译：用于检测作为癌症生物标记物的PLECTIN-1的组合物和方法
公开(公告)号：WO2011057078A2
公开(公告)日：2011-05-12
申请号：PCT/US2010/055632
申请日：2010-11-05
申请人： UNIVERSITY OF VIRGINIA PATENT FOUNDATION , KELLY, Kimberly A.
发明人： KELLY, Kimberly A.
IPC分类号： G01N33/68 , G01N33/58 , G01N33/574
CPC分类号： A61K51/088 , A61K47/64 , A61K49/0002 , A61K51/0482 , A61K51/065 , C07K7/06 , C07K14/00 , G01N33/531 , G01N33/574 , G01N2333/4724
摘要： The present invention provides compositions and methods useful for diagnostic and imaging techniques for detecting and localizing the biomarker Plectin-1. The present invention provides multimeric peptide ligand complexes for targeting Plectin-1, such as the multimeric peptide ligand complex having the formula (βAKTLLPTPGGS(PEG5000))4 KKKKDOTAβA-NH 2 , to which imaging agents and/or therapeutic agents can be conjugated.
摘要翻译：本发明提供了用于检测和定位生物标志物Plectin-1的诊断和成像技术的组合物和方法。本发明提供用于靶向Plectin-1的多聚体肽配体复合物，例如具有式（ßAKTLLPTPGGS（PEG5000））4KKKKDOTAßA-NH 2的多聚体肽配体复合物，成像剂和/或治疗剂可以结合到其上。

10. 发明申请

WO2009129220A3 PLECTIN-1 TARGETED AGENTS FOR DETECTION AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA 审中-公开
公开(公告)号：WO2009129220A3
公开(公告)日：2009-10-22
申请号：PCT/US2009/040480
申请日：2009-04-14
申请人： THE GERERAL HOSPITAL CORPORATION , KELLY, Kimberly , WEISSLEDER, Ralph , BARDEESY, Nabeel
发明人： KELLY, Kimberly , WEISSLEDER, Ralph , BARDEESY, Nabeel
IPC分类号： C07K7/06 , A61K49/14 , A61K38/08 , G01N33/574 , G01N33/68
摘要： Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying "accessible" proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式